NCCN guidelines updated to recommend PEDMARK for reducing cisplatin-induced hearing loss in pediatric AYA patients.

FENNEC PHARMACEUTICALS INC.

NCCN AYA Oncology guidelines now recommend PEDMARK to reduce cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors.
PEDMARK, FDA-approved Sept 2022 and commercially launched Oct 2022, is first and only therapy for this indication.
Hearing loss occurs in ~60% (up to 90%) of children treated with cisplatin; PEDMARK may reduce risk based on Phase 3 trials.
FDA labeling states PEDMARK is not substitutable with other sodium thiosulfate products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.